Study group characteristics
| Bronchiectasis(n = 44) | Cystic fibrosis(n = 44) | |
|---|---|---|
| BMT, bone marrow transplant. | ||
| *⩾1 occasion over study period. | ||
| †Non-typeable, ⩾3 positive cultures in 1 year. | ||
| ‡25 (59%) of those with CF were prescribed inhaled corticosteroids. | ||
| Spirometric studies (median per individual) | 931 (15) | 2066 (45) |
| Mean calendar years of data | 4.7 years | 6.7 years |
| Lung volume studies (median per individual) | 368 (7) | 621 (13) |
| Mean (range) age at testing(all studies), years | 10.7 (5–15) | 10.1 (5–15) |
| Sex: % female | 57% | 48% |
| Ethnicity, n (%) | ||
| Maori | 12 (27%) | 2 (5%) |
| European | 7 (16%) | 40 (91%) |
| Pacific | 25 (57%) | 0 (0%) |
| Other | 0 (0%) | 2 (5%) |
| BX aetiology | ||
| Unknown | 22 (50%) | |
| Post-infectious | 7 (16%): 6 due to adenovirus,1 to B pertussis | |
| Primary immunodeficiency | 6 (14%): 5 humoral, 1 combined deficiencies | |
| “Post-oncology disease/Rx” | 6 (14%): 4 leukaemia (2 BMT),2 lymphoma | |
| Other | 3 (7%) | |
| Asthma diagnosis | 17 (39%) | 5 (11%)‡ |
| β2 agonist response >12%*19 | 21 (48%) | 31 (70%) |
| Median (range) CT score | 24 (4–65) | |
| Laterality of disease | 89% bilateral | |
| Median diseased lobes | 4 (5% unilobular) | |
| Chronic Haemophilus influenza infection†9 | 18 (41%) | |
| Chronic Pseudomonas infection | 0 (0%) | 24 (55%) |
| Median age at diagnosis (initiation of specific treatment) | 7.5 years | 1 month |